Mondias Completes Characterization of CELEXT07 that Confirms Its Biostimulant and Antifungal Capabilities and Expands Its Global Market Potential

MONTREAL, Feb. 12, 2019 /CNW/ – Mondias Naturals Inc (“Mondias” or “NHP”), (TSXV: NHP), announces that the research collaboration with McGill University has led to the identification of CELEXT07 signatory metabolite compounds, antibiotic properties and functional roles in plant physiology. This will lead to the development of several commercial products to meet emerging needs in bio-agricultural and organic markets and offer new chemical free solutions for the cultivation and food storage industries.

The chemical classes of compounds identified in the CELEXT07 extract confirms the botanical agent’s properties associated with plant defense against biotic stress by boosting the plant’s resistance as well as a biostimulant effect on growth.  The identification of these compounds supports the previous research demonstrating CELEXT07’s biostimulant and antifungal protective and treatment properties.

Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results validate Mondias’ strategy to develop natural products for agricultural markets including post-harvest sub-markets. The CELEXT07 botanical extract will make a significant contribution to the bio-agricultural and organic markets and allow growers to offer horticultural products grown with no chemical agents.  We are excited by this advancement since CELEXT07 is an eco-friendly alternative to synthetic fungicides.”

Postharvest diseases caused by storage fungi are responsible for the estimated loss of about 20 to 25% of harvested fruits and vegetables, and will certainly affect Canada’s new cannabis industry.  Some fungi may produce mycotoxins that can cause toxicity to both animals and humans. Mycotoxin contaminations can occur in the field and greenhouse, before and after harvest, and also during post-harvest activities and storage.  Mondias has been developing its CELEXT07 products to help prevent fungal growth on plants through its proven ability to increase plants’ defense system.

As previously reported in its December 5, 2018 news release, CELEXT07, when used as a soil drench agent, significantly reduced lesions caused by fungi on two greenhouse growing plants, tomato and lettuce, and significantly reduced lesions on detached leaves.  Mondias has been expanding its research activities to target food and crop storage. Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results suggest that CELEXT07 botanical extract may become a low-risk solution to the new Canadian and USA cannabis agricultural industries.”

The market potential for CELEXT07 is considerable considering that these infections result in annual economic losses between $10 billion to $100 billion worldwide (L. Hua et al. 2018) and that about one-third of the food produced worldwide for human consumption is lost after harvest (Gastavsson et al., 2011).

About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care, bio agriculture and organic markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.

For more information, visit: mondias.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture,  the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.